Diabetes, Vol 44, Issue 8 984-991, Copyright © 1995 by American Diabetes Association

ARTICLES

Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance

CJ de Souza, JH Yu, DD Robinson, RG Ulrich and MD Meglasson
Department of Endocrine Pharmacology, Upjohn Laboratories, Kalamazoo, Michigan 49001, USA.

The role of insulin resistance in the impaired glucose-stimulated insulin release of Zucker fatty rats was investigated using the insulin-sensitizing thiazolidinedione drug pioglitazone. Fatty rats had fasting hyperinsulinemia yet a blunted secretory response to intravenous glucose compared with lean age-matched controls. Islets from fatty rats secreted less insulin (based on islet DNA) in response to high glucose than islets from lean rats but secreted normal amounts of insulin when tolbutamide or alpha-ketoisocaproic acid (alpha-KIC) was the stimulus. Administering pioglitazone for 9 days diminished basal hyperinsulinemia and increased the insulin response to high glucose by fatty rats but not by lean controls. Pioglitazone pretreatment augmented the secretory response by isolated islets to high glucose, alpha-KIC, and tolbutamide. Augmentation of islet insulin release was not associated with reduced plasma glucose concentration, suggesting that altered glycemia was not involved. Pancreas and islet insulin content was greater in fatty rats than in lean controls and was decreased by pioglitazone; hence, insulin stores and glucose-stimulated insulin release did not correlate. Pioglitazone treatment did not affect the rate of islet glucose usage or ATP/ADP in the presence of 2.75 or 16 mmol/l glucose. These data indicate that ameliorating insulin resistance reverses defective glucose-stimulated insulin release by Zucker fa/fa rats. After pioglitazone administration, insulin secretion may be augmented by increased generation of a metabolic coupling factor from glucose or at a later step in the secretory process that is common to both glucose and nonglucose secretagogues.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban Pioglitazone and Sodium Salicylate Protect Human {beta}-Cells against Apoptosis and Impaired Function Induced by Glucose and Interleukin-1{beta} J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5059 - 5066. [Abstract] [Full Text] [PDF]

				A. R. Diani, G. Sawada, B. Wyse, F. T. Murray, and M. Khan Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E116 - E122. [Abstract] [Full Text]

				K. Yajima, H. Hirose, H. Fujita, Y. Seto, H. Fujita, K. Ukeda, K. Miyashita, T. Kawai, Y. Yamamoto, T. Ogawa, et al. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E966 - E971. [Abstract] [Full Text] [PDF]

				L. Madsen, M. Guerre-Millo, E. N. Flindt, K. Berge, K. J. Tronstad, E. Bergene, E. Sebokova, A. C. Rustan, J. Jensen, S. Mandrup, et al. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance J. Lipid Res., May 1, 2002; 43(5): 742 - 750. [Abstract] [Full Text] [PDF]

				S. E. Kahn The Importance of {beta}-Cell Failure in the Development and Progression of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4047 - 4058. [Full Text] [PDF]

				C. J. de Souza, M. Eckhardt, K. Gagen, M. Dong, W. Chen, D. Laurent, and B. F. Burkey Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting of Obesity and Insulin Resistance Diabetes, August 1, 2001; 50(8): 1863 - 1871. [Abstract] [Full Text] [PDF]

				S. A. Lloyd-MacGilp, S. M. Nelson, M. Florin, M. Lo, J. McKinnell, J. Sassard, and C. J. Kenyon 11{beta}-Hydroxysteroid Dehydrogenase and Corticosteroid Action in Lyon Hypertensive Rats Hypertension, November 1, 1999; 34(5): 1123 - 1128. [Abstract] [Full Text] [PDF]

				M. Guerre-Millo, P. Gervois, E. Raspe, L. Madsen, P. Poulain, B. Derudas, J.-M. Herbert, D. A. Winegar, T. M. Willson, J.-C. Fruchart, et al. Peroxisome Proliferator-activated Receptor alpha Activators Improve Insulin Sensitivity and Reduce Adiposity J. Biol. Chem., May 26, 2000; 275(22): 16638 - 16642. [Abstract] [Full Text] [PDF]